Biotech firm PepGen's Q3 net loss narrows to $18 mln

PepGen

12/11/2025 12:11

Overview

PepGen Q3 net loss narrows to $18 mln from $21.4 mln in 2024

Company raised $115 mln, extending cash runway into 2H 2027

FREEDOM-DM1 study shows highest mean splicing correction in DM1 patients

Outlook

PepGen expects FREEDOM2 5 mg/kg cohort results in Q1 2026

Company plans to initiate 10 mg/kg dosing in FREEDOM2 in Q1 2026

PepGen's cash runway extended into second half of 2027

Result Drivers

Research and Development Expenses were $13.4 million for the three months ended September 30, 2025, compared to $17.7 million for the same period in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.52
Q3 Net Income
-$18.03 mln
Q3 Operating Expenses
$18.65 mln
Q3 Operating Income
-$18.65 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for PepGen Inc is $9.00, about 48.3% above its November 11 closing price of $4.65

Press Release: ID:nBwb11Pbha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)